Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
An established industry player is seeking a dynamic Computational Chemist to spearhead drug discovery efforts using cutting-edge AI/ML technologies. This role involves leading virtual screening campaigns, collaborating with medicinal chemists, and growing the Computational Chemistry team. You will teach key principles to colleagues while improving processes from computational hits to experimental leads. Join a forward-thinking startup that is revolutionizing drug development in a supportive and innovative environment, where your contributions will significantly impact the future of medicine.
1910 Genetics is the only company that has built a synergistic, dual-purpose small and large molecule platform that integrates artificial intelligence (AI), computation, and biological automation to design drug-like molecules better, faster, and cheaper than traditional approaches. Based in the Seaport District of Boston, 1910 Genetics is a Series A stage biotechnology startup that was founded in 2018 and is backed by prestigious investors, including M12-Microsoft’s Venture Fund, Sam Altman – the CEO of OpenAI (makers of ChatGPT), Playground Global, Y Combinator, New Ventures Funds (Scientia Ventures), and many others.
At 1910 Genetics, we first established an understanding of the molecular basis of disease to the granularity at which the world understands sickle cell anemia. This understanding centers biology as our North Star and drives our integration of artificial intelligence (AI), computation, and biological automation to accelerate the design of small molecule and protein therapeutics.
Recent advances in computational technologies have placed historically “undruggable” targets within therapeutic reach. But at 1910 Genetics, we often say “Biology is King,” meaning that computational technologies are only impactful in drug discovery when driven by experimental biology. Our platforms’ scale and breadth empower us to be therapeutic area-agnostic with programs ranging from neuroscience and immunology to infectious disease and oncology, to name a few.